Emergo Therapeutics
Bringing the Immune Response Back into Balance
Bringing the Immune Response Back into Balance
Emergo Therapeutics is a biopharmaceutical startup that stands out in the industry with its mission of bringing the immune response back into balance. Established in 2017, the company operates in the Biopharma, Biotechnology, and Pharmaceutical sectors, with its headquarters in the United States.
The most recent milestone for Emergo Therapeutics was its $3.52M Venture Round investment on 12 October 2020. This signifies a major endorsement of the company's vision and capabilities by the investment community.
As an analyst, the innovative and impactful nature of Emergo's work is evident, and the recent investment round indicates a strong vote of confidence in the potential of the startup. With the backing of notable investors, Emergo Therapeutics is poised to make significant strides in revolutionizing immune response management and shaping the future of biopharmaceuticals.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $3.52M | - | 12 Oct 2020 | |
| Debt Financing | $500.00K | 1 | North Carolina Biotechnology Center | 15 Oct 2019 |
| Series A | $12.00M | 5 |
|
23 May 2018 |
No recent news or press coverage available for Emergo Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
